Mechanism-based treatments in neurodevelopmental disorders: Fragile X syndrome

Pediatric Neurology

Volumn 50, Issue 4, 2014, Pages 297-302

  Berry Kravis, Elizabeth ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

autism; dendritic translation; FMRP; fragile X syndrome; GABA agonists; metobotropic glutamate receptors; signal transduction; synaptic plasticity

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; FRAGILE X MENTAL RETARDATION PROTEIN; MAVOGLURANT;

AUTISM; CROSSOVER PROCEDURE; DENDRITIC SPINE; DOUBLE BLIND PROCEDURE; FRAGILE X SYNDROME; GENE PRODUCT; HUMAN; INTELLECTUAL IMPAIRMENT; KNOCKOUT MOUSE; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRINUCLEOTIDE REPEAT; ANIMAL; BRAIN; DEVELOPMENTAL DISABILITIES; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; DENDRITIC SPINES; DEVELOPMENTAL DISABILITIES; FRAGILE X SYNDROME; HUMANS;

EID: 84896400422     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2013.12.001     Document Type: Review

References (37)

1. B. Coffee, K. Keith, and I. Albizua et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA Am J Hum Genet 85 2009 503 514
2. R. Willemsen, J. Levenga, and B.A. Oostra CGG repeat in the FMR1 gene: size matters Clin Genet 80 2011 214 225
3. M.M. Seltzer, M.W. Baker, J. Hong, M. Maenner, J. Greenberg, and D. Mandel Prevalence of CGG expansions of the FMR1 gene in a US population-based sample Am J Med Genet B Neuropsychiatr Genet 159B 2012 589 597
4. F. Tassone, K.P. Iong, and T. Tong et al. FMR1 CGG allele size and expansion prevalence ascertained through newborn screening in the United States Genome Med 4 2012 100
5. R.J. Hagerman, E. Berry-Kravis, and W.E. Kaufmann et al. Advances in the treatment of fragile X syndrome J Pediatr 123 2009 378 390
6. E. Berry-Kravis, A. Sumis, C. Hervey, and S. Mathur Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome Int J Pediatr 2012 2012 843016
7. L.W. Wang, E. Berry-Kravis, and R.J. Hagerman Fragile X: leading the way for targeted treatments in autism Neurotherapeutics 7 2010 264 274
8. E. Berry-Kravis, M. Raspa, L. Loggin-Hester, E. Bishop, D. Holiday, and D. Bailey Seizures in fragile X syndrome: characteristics and co-morbid diagnoses Am J Intellect Dev Disabil 115 2010 461 472
9. D.Z. Loesch, R.M. Huggins, and R.J. Hagerman Phenotypic variation and FMRP levels in fragile X Ment Retard Dev Disabil Res Rev 10 2004 31 41 (Pubitemid 38375351)
10. D.B. Bailey Jr., M. Raspa, E. Bishop, M. Olmsted, U. Malya, and E. Berry-Kravis Medication utilization for targeted symptoms in children and adults with fragile X syndrome: U.S. survey J Dev Behav Pediatr 33 2012 62 69
11. The Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragile X mental retardation Cell 78 1994 23 33
12. A.W. Grossman, G.M. Aldridge, I.J. Weiler, and W.T. Greenough Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond J Neurosci 26 2006 7151 7155
13. K.M. Huber, S.M. Gallagher, S.T. Warren, and M.F. Bear Altered synaptic plasticity in a mouse model of fragile X mental retardation Proc Natl Acad Sci USA 99 2002 7746 7750 (Pubitemid 34568762)
14. E. Berry-Kravis, A. Knox, and C. Hervey Targeted treatments for fragile X syndrome J Neurodev Disord 3 2011 193 210
15. C. Bagni, F. Tassone, G. Neri, and R. Hagerman Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics J Clin Invest 122 2012 4314 4322
16. M.F. Bear, K.M. Huber, and S.T. Warren The mGluR theory of fragile X mental retardation Trends Neurosci 27 2004 370 377 (Pubitemid 38829251)
17. Q.J. Yan, M. Rammal, M. Tranfaglia, and R.P. Bauchwitz Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP Neuropharmacology 49 2005 1053 1066 (Pubitemid 41503304)
18. F.M. de Vrij, J. Levenga, and H.C. van der Linde et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice Neurobiol Dis 31 2008 127 132 (Pubitemid 351822560)
19. G. Dolen, E. Osterweil, and B.S. Shankaranarayana Rao et al. Correction of fragile X syndrome in mice Neuron 56 2007 955 962 (Pubitemid 350251119)
20. S.M. McBride, C.H. Choi, and Y. Wang et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a model of fragile X syndrome Neuron 45 2005 753 764 (Pubitemid 40320709)
21. A. Michalon, M. Sidorov, and T.M. Ballard et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice Neuron 74 2012 49 56
22. C.J. Yuskaitis, M.A. Mines, M.K. King, J.D. Sweatt, C.A. Miller, and R.S. Jope Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome Biochem Pharmacol 79 2010 632 646
23. E. Berry-Kravis, A. Sumis, and C. Hervey et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome J Dev Behav Pediatr 29 2008 293 302
24. T.V. Bilousova, L. Dansie, and M. Ngo et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model J Med Genet 46 2009 94 102
25. C. Paribello, L. Tao, and A. Folino et al. Open-label add-on treatment trial of minocycline in fragile X syndrome BMC Neurol 10 2010 91
26. M.J. Leigh, D.V. Nguyen, and Y. Mu et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome J Dev Behav Pediatr 34 2013 147 155
27. S. Chang, S.M. Bray, and Z. Li et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila Nat Chem Biol 4 2008 256 263 (Pubitemid 351419125)
28. L.K. Pacey, S.P. Heximer, and D.R. Hampson Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures Mol Pharmacol 76 2009 18 24
29. C. Henderson, L. Wijetunge, and M.N. Kinoshita et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen Sci Transl Med 4 2012 152ra128
30. E. Berry-Kravis, D. Hessl, and B. Rathmell et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial Sci Transl Med 4 2012 152ra127
31. S. Maltas, K.F. Widaman, and S. Hall et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment J Autism Dev Disord 42 2012 1377 1392
32. C.A. Erickson, L.K. Wink, and B. Ray et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome Psychopharmacology (Berl) 228 2013 75 84
33. E. Berry-Kravis, D. Hessl, and S. Coffey et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J Med Genet 46 2009 266 271
34. S. Jacquemont, A. Curie, and V. des Portes et al. Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5antagonist AFQ056 Sci Trans Med 3 2011 64ra1
35. E Berry-Kravis, D Hessl, and L Abbeduto et al. Outcome measures for fragile X syndrome clinical trials: Consensus Statement from the NIH Fragile X Coordinating Group J Dev Behav Pediatr 34 2013 508 522
36. F. Farzin, F. Scaggs, C. Hervey, E. Berry-Kravis, and D. Hessl Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome J Autism Dev Disord 41 2011 1515 1522
37. I. Iossifov, M. Ronemus, and D. Levy et al. De novo gene disruptions in children on the autistic spectrum Neuron 74 2012 285 299